Valuation: Atrion Corporation

Market Cap 809M 710M 658M 605M 1.14B 77.47B 1.17B 7.84B 3.07B 38.05B 3.04B 2.97B 131B P/E 2022
28.6x
P/E 2023 34.4x
Enterprise Value 803M 705M 653M 601M 1.14B 76.9B 1.16B 7.78B 3.05B 37.76B 3.02B 2.95B 130B EV / Sales 2022
5.27x
EV / Sales 2023 3.9x
Free-Float
50.88%
Yield 2022
1.47%
Yield 2023 2.3%
3 years 274.98
Extreme 274.98
593
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 21/08/2024
Director TitleAgeSince
Director/Board Member 53 21/08/2024
Date Insider Type Main position Quantity % Market Cap.
21/08/24Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24Issuer sale

Chief Financial Officer

2,223 0.1263%
21/08/24Issuer sale

Chairman

150,927 8.5756%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--%-.--%-15.04% 809M
-1.94%-3.68%-30.23%-14.51% 164B
-0.36%+0.61%-7.06%-5.09% 107B
+0.89%+2.54%+3.70%+60.04% 59.04B
+0.69%+0.45%+41.39%+56.93% 51.72B
+1.24%-1.10%-12.58%-40.82% 41.87B
-1.12%-6.04% - - 34.7B
+1.85%+7.16%-8.42%-42.88% 28.93B
+1.69%+0.58%+58.33%-6.25% 24.99B
+0.49%+1.77%-4.82%-5.11% 21.05B
Average +0.36%-1.00%+4.48%-1.41% 53.41B
Weighted average by Cap. -0.27%-0.94%-5.53%+0.69%

Financials

2022 2023
Net sales 184M 161M 149M 137M 259M 17.56B 264M 1.78B 697M 8.63B 689M 674M 29.79B 169M 149M 138M 127M 239M 16.21B 244M 1.64B 643M 7.96B 636M 622M 27.49B
Net income 35.01M 30.71M 28.44M 26.17M 49.49M 3.35B 50.46M 339M 133M 1.65B 131M 129M 5.68B 19.41M 17.03M 15.77M 14.51M 27.44M 1.86B 27.98M 188M 73.71M 912M 72.89M 71.3M 3.15B
Net Debt -25.21M -22.11M -20.48M -18.84M -35.64M -2.41B -36.34M -244M -95.74M -1.18B -94.67M -92.6M -4.09B -6.02M -5.28M -4.89M -4.5M -8.51M -576M -8.67M -58.25M -22.85M -283M -22.59M -22.1M -977M
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock